by Melanoma Institute Australia
Melanoma Insights for Professionals features interviews with leading melanoma specialists who translate the latest research and best practice into the everyday clinic setting. Developed by Melanoma Institute Australia, this series is for multidisciplinary healthcare professionals who want to be across the latest developments in melanoma. For more education, visit melanomaeducation.org.au.
Language
🇺🇲
Publishing Since
3/22/2019
Email Addresses
1 available
Phone Numbers
0 available
November 5, 2024
<p>In this special podcast recorded from the <a href="https://www.melanoma2024.com/" target="_blank" rel="ugc noopener noreferrer">2024 Australasian Melanoma Conference</a>, we hear from our international keynote speakers, Prof Susan Swetter and Prof Olivier Michelin, about what excites them in the field of melanoma research.</p> <p><br /></p> <p>Interviewed by AMC2024 Co-Chairs, Prof Georgina Long AO and Prof Richard Scolyer AO, our guests provide their multidisciplinary perspectives and highlight the importance of working together to make an impact in melanoma prevention and patient care.</p> <p><br /></p> <p>Dermatologist Prof Swetter discusses the evolving role of AI in dermatology and the clinical diagnosis of melanoma, and highlights the opportunity for improved prevention strategies in the US to reduce the incidence of melanoma.</p> <p><br /></p> <p>Prof Michelin explores how we’re tackling advanced melanoma, in particular to maximize our current treatment tools and manage drug toxicities. He also discusses expanding access to neoadjuvant therapies and the potential of TIL therapies, alongside AI advancements in histopathological diagnosis to personalise treatment approaches.</p> <p><br /></p> <p>This podcast is suitable for multidisciplinary healthcare professionals and researchers.</p> <p><br /></p> <p>SPEAKERS</p> <ul> <li><strong>Prof Georgina Long AO</strong> - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney |2024 Joint Australian of the Year</li> </ul> <ul> <li><strong>Prof Richard Scolyer AO</strong> - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney |2024 Joint Australian of the Year</li> </ul> <ul> <li><strong>Prof Susan Swetter</strong> - Professor of Dermatology, Co-Director of the Pigmented Lesion/Melanoma and Cutaneous Oncology Programs, Stanford University Medical Center and Cancer Institute | Chair, National Comprehensive Cancer Network Melanoma Panel</li> </ul> <ul> <li><strong>Prof Olivier Michelin</strong> - Chair, Department of Oncology and the Precision Oncology Service, Geneva University Hospital | Co-Director, Swiss Cancer Centre Léman| Vice-Coordinator, Translational Research Centre in Onco-Hematology</li> </ul> <p><br /></p> <p>Please note that this podcast was accurate at the time of recording (October 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.</p> <p><br /></p> <p><a href="https://melanomaeducation.org.au/" target="_blank" rel="ugc noopener noreferrer">MIA’s Education Program</a> is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.</p>
September 2, 2024
<p>Comprehensive infrastructure is essential to driving research progress and improving patient care.</p> <p><br></p> <p>In this podcast, A/Prof Sydney Ch’ng leads an insightful discussion on the groundbreaking research infrastructure that underpins the many groundbreaking achievements at Melanoma Institute Australia. The discussion highlights the Institute’s clinical trial program, translational research, biospecimen bank and melanoma research database, offering a closer look at the critical elements driving progress.</p> <p><br></p> <p>This podcast is suitable for multidisciplinary healthcare professionals, researchers and clinical trials staff.</p> <p><br></p> <p>SPEAKERS</p> <p><br></p> <p>A/Prof Sydney Ch’ng</p> <p>Plastic & Reconstructive Surgeon and Head & Neck Surgeon, Melanoma Institute Australia | Associate Professor of Surgery, The University of Sydney</p> <p><br></p> <p>Prof Helen Rizos</p> <p>Cancer Cell Biologist and Research Lead in the Faculty of Medicine, Health and Human Sciences at Macquarie University | Faculty Member, Melanoma Institute Australia</p> <p><br></p> <p>A/Prof Serigne Lo</p> <p>Senior Biostatistician, Melanoma Institute Australia | Associate Professor of Biostatistics, The University of Sydney</p> <p><br></p> <p>Maria Gonzalez</p> <p>Director of Clinical Care, Melanoma Institute Australia</p> <p><br></p> <p>Dr Nicole Caixeiro</p> <p>Head of the Biospecimen Bank, Melanoma Institute Australia</p> <p><br></p> <p><br></p> <p>Please note that this podcast was accurate at the time of recording (August 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.</p> <p><br></p> <p>LINKS</p> <p><br></p> <p>2024 Australasian Melanoma Conference</p> <p><br></p> <p>Melanoma Education Portal</p> <p><br></p> <p><br></p> <p><br></p> <p>MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.</p>
June 3, 2024
<p>Neoadjuvant immunotherapy is transforming patient care in the field of melanoma. New research recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting is set to change melanoma treatment protocols globally, and likely to have significant impact on treatment for other cancers too.</p> <p><br></p> <p>In this podcast, A/Prof Matt Carlino leads an engaging discussion with MIA’s Prof Georgina Long AO, A/Prof Alex Menzies and A/Prof Alex van Akkooi as they discuss the pivotal results from the NADINA trial and how this will undoubtedly change the standard of care for Stage III melanoma patients. They also discuss the practical implications for implementing this treatment regime, including relevant patient populations, toxicity, impacts for surgery and future directions.</p> <p><br></p> <p>This podcast is suitable for Medical Oncologists, Surgical Oncologists, Pathologists, Researchers, GPs Oncology Nurses and other healthcare professionals. It is produced by <a href="http://www.melanoma.org.au/" target="_blank" rel="noopener noreferer">Melanoma Institute Australia. </a></p> <p><br></p> <p>SPEAKERS</p> <ul> <li><strong>A/Prof Matteo Carlino</strong> - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney</li> <li><strong>Prof Georgina Long AO </strong>- Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney</li> <li><strong>A/Prof Alexander Menzies</strong> - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney</li> <li><strong>A/Prof Alexander van Akkooi</strong> - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney</li> </ul> <ul> <br></ul> <p>PUBLICATIONS</p> <ul> <li>Blank C, Lucas MW, Scolyer RA, et al. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2402604">Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma</a>. <em>N Engl J Med </em>2024. DOI: 10.1056/NEJMoa2402604</li> <li>Patel SP, Othus M, Chen Y, et al. <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2211437" target="_blank" rel="noopener noreferer">Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma</a>. <em>N Engl J Med</em> 2023;388:813-823.</li></ul> <p><br></p> <p>FURTHER EDUCATION</p> <ul> <li>Podcast: <a href="https://melanomaeducation.org.au/courses/melanoma183/" target="_blank" rel="noopener noreferer">Neoadjuvant immunotherapy: Revolutionising melanoma treatment</a></li></ul> <ul> <li>Video: <a href="https://melanomaeducation.org.au/courses/melanoma177/" target="_blank" rel="noopener noreferer">The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists</a></li></ul> <ul> <li>Conference: <a href="https://www.melanoma2024.com/" target="_blank" rel="noopener noreferer">2024 Australasian Melanoma Conference</a></li></ul> <ul> <br></ul> <p>Please note that this podcast was accurate at the time of recording (2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.</p> <p><br></p> <p><a href="https://melanomaeducation.org.au/" target="_blank" rel="noopener noreferer">MIA’s Education Program</a> is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.</p>
AIM at Melanoma Foundation
Stuart Wemyss
BBC Radio 4
ZOE
Chat 10 Looks 3
BBC Radio 4
The Economist
Vox Media Podcast Network
Daily Stoic | Wondery
DOAC
Vox Media Podcast Network
Pushkin Industries
Sam and Karine
Mel Robbins
Peter Attia, MD
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.